Do clinical , histological or immunohistochemical primary tumor characteristics translate into different 18 FDG-PET / CT volumetric and heterogeneity features in stage II-III breast cancer ?
暂无分享,去创建一个
M. Hatt | F. Tixier | D. Visvikis | C. Rest | M. Majdoub | D. Groheux | A. Martineau | P. Merlet | M. Espié | A. Roquancourt | E. Hindié | Pascal Merlet | Elif | Hindié
[1] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[2] H. Yagata,et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[18F]‐D‐glucose , 1998, Cancer.
[3] Peter Bartenstein,et al. Overexpression of Glut‐1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma , 2003, Cancer.
[4] David L. Schwartz,et al. Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.
[5] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[6] Issam El-Naqa,et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes , 2009, Pattern Recognit..
[7] Christian Roux,et al. A Fuzzy Locally Adaptive Bayesian Segmentation Approach for Volume Determination in PET , 2009, IEEE Transactions on Medical Imaging.
[8] Yun Yen,et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] Dimitris Visvikis,et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. , 2010, International journal of radiation oncology, biology, physics.
[10] M. Mohty,et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[11] S. Rodenhuis,et al. The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy , 2010, Annals of Surgical Oncology.
[12] Marc Espié,et al. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[13] D. Groheux,et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[14] R. Jeraj,et al. Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters , 2010, Acta oncologica.
[15] M. Hatt,et al. Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer , 2011, The Journal of Nuclear Medicine.
[16] Drew A. Torigian,et al. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[17] Ronald Boellaard,et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[18] M. Hatt,et al. Reproducibility of Tumor Uptake Heterogeneity Characterization Through Textural Feature Analysis in 18F-FDG PET , 2012, The Journal of Nuclear Medicine.
[19] D. Groheux,et al. Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer , 2012, Journal of the National Cancer Institute.
[20] Patrick Granton,et al. Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.
[21] S. Rodenhuis,et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[22] D. Narayanan,et al. Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[23] M. Hatt,et al. Comparison Between 18F-FDG PET Image–Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer , 2013, The Journal of Nuclear Medicine.
[24] Vicky Goh,et al. Are Pretreatment 18F-FDG PET Tumor Textural Features in Non–Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy? , 2013, The Journal of Nuclear Medicine.
[25] C. Coutant,et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[26] H. Linden,et al. Novel methods and tracers for breast cancer imaging. , 2013, Seminars in nuclear medicine.
[27] C. Coutant,et al. 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[28] S. Glück,et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657 , 2013 .
[29] M. Hatt,et al. Robustness of intratumour 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[30] A. Alavi,et al. Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. , 2014, Cancer research.
[31] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[32] S. Son,et al. Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast , 2014, BMC Cancer.
[33] Vicky Goh,et al. Correlation of Intra-Tumor 18F-FDG Uptake Heterogeneity Indices with Perfusion CT Derived Parameters in Colorectal Cancer , 2014, PloS one.
[34] Ross Berbeco,et al. Comparison of Texture Features Derived from Static and Respiratory-Gated PET Images in Non-Small Cell Lung Cancer , 2014, PloS one.
[35] F. Brooks,et al. The Effect of Small Tumor Volumes on Studies of Intratumoral Heterogeneity of Tracer Uptake , 2014, The Journal of Nuclear Medicine.
[36] I. Apostolova,et al. Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer , 2014, European Radiology.
[37] Sung-Bae Kim,et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. , 2014, The Lancet. Oncology.
[38] Evaluating heterogeneity of primary tumor 18F-FDG uptake in breast cancer with a dedicated breast PET (MAMMI): a feasibility study based on correlation with PET/CT , 2014, Nuclear medicine communications.
[39] Florent Tixier,et al. Visual Versus Quantitative Assessment of Intratumor 18F-FDG PET Uptake Heterogeneity: Prognostic Value in Non–Small Cell Lung Cancer , 2014, The Journal of Nuclear Medicine.
[40] M. Soussan,et al. Relationship between Tumor Heterogeneity Measured on FDG-PET/CT and Pathological Prognostic Factors in Invasive Breast Cancer , 2014, PloS one.
[41] D. Groheux,et al. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[42] M. Hatt,et al. 18F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi–Cancer Site Patient Cohort , 2015, The Journal of Nuclear Medicine.